{"name":"BioXcel Therapeutics Inc","slug":"bioxcel-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"BXCL501 Sublingual Film","genericName":"BXCL501 Sublingual Film","slug":"bxcl501-sublingual-film","indication":"Acute agitation associated with schizophrenia or bipolar I disorder","status":"phase_2"},{"name":"Sublingual film containing Igalmi","genericName":"Sublingual film containing Igalmi","slug":"sublingual-film-containing-igalmi","indication":"Acute agitation associated with schizophrenia or bipolar disorder","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo film","genericName":"Placebo film","slug":"placebo-film","indication":"Clinical trial control comparator (indication dependent on active drug being studied)","status":"phase_3"}]}],"pipeline":[{"name":"BXCL501 Sublingual Film","genericName":"BXCL501 Sublingual Film","slug":"bxcl501-sublingual-film","phase":"phase_2","mechanism":"BXCL501 is a selective serotonin reuptake inhibitor (SSRI) that modulates serotonin levels in the brain to treat acute agitation.","indications":["Acute agitation associated with schizophrenia or bipolar I disorder"],"catalyst":""},{"name":"Placebo film","genericName":"Placebo film","slug":"placebo-film","phase":"phase_3","mechanism":"A placebo film formulation serves as an inert control comparator in clinical trials to assess the efficacy of active pharmaceutical agents.","indications":["Clinical trial control comparator (indication dependent on active drug being studied)"],"catalyst":""},{"name":"Sublingual film containing Igalmi","genericName":"Sublingual film containing Igalmi","slug":"sublingual-film-containing-igalmi","phase":"marketed","mechanism":"Igalmi is a fast-acting atypical antipsychotic that rapidly dissolves under the tongue to block dopamine and serotonin receptors in the brain.","indications":["Acute agitation associated with schizophrenia or bipolar disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBxMHdsbXhYT1R2eDJMQnJwdE9ZM0J4TWxRMTBQR0hUa2NkQ2lTNkx3enoxSmNFc3dHc1U1T01nWHRuYzg2YkhkM3l5MmZkYlRtUEVLMERqdzFRMGFmUmdHY3NZRTdnbXZZNGplTHVB?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI) - Stock Titan","headline":"If You Invested $1,000 in Bioxcel Therapeutics Inc (BTAI)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOV2ZMQ1VlejBOaHJtUEt2d3VoSXYxc1AzOXg5V3RaQ0lXc2Q3Zm8xRXo0YzFUVm1YdXNyY25rM0dSaGNCQUxCelZRaGZYLTJ1aFJ5UzNRaDJRLVBSeFE5YVFvb0lncjY5WjBMV1dKX1RPa3JiQmQ2bkpGdXh6S0NMNzlhbFp2MjVsb1NVNUdYaVlMQ1JPSGVpTUhKVTBSSHl0OXdZbw?oc=5","date":"2026-02-03","type":"pipeline","source":"Stock Titan","summary":"Veteran biotech commercial leader Michael P. Miller joins Rigel board - Stock Titan","headline":"Veteran biotech commercial leader Michael P. Miller joins Rigel board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNTDBXaEdKWXBkclZjY1FXRTlqdmtMb25sUnotMU40QXBjbVJucjU1R3RjbDVqM0kzYkVad3JUX0dKYXlMRHFoeFE4N1RPZ1pBdnhhSFBjZjNGWGh2cWZBVU50T2dITnAxMWI2MnJkcm5mS05pa0tZRXNXRTdicVdVS2c1OGJ6NXE4LXlkNEtUblJkTlVKdHRIVTYtM0hEMFBoeDBQYUxpYzRHRmNXeU56WmM1NGYyc3RveG1xaUpwMXg5MlF2ck9oYm1aYVV6VWc1em1uOTNn?oc=5","date":"2025-08-27","type":"regulatory","source":"Reuters","summary":"BioXcel to seek approval for at-home use of agitation drug after upbeat study - Reuters","headline":"BioXcel to seek approval for at-home use of agitation drug after upbeat study","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBBRE13TnhmbmE5dzlvZDBfdWg4ajFDUmhDVTVuQnJEZzV3dmxwNXVZNUZmNGU3YnFaNGlOSnR5U1JCa0lSX1R1V3o4aGl0NkRKbmJV?oc=5","date":"2025-08-27","type":"trial","source":"FirstWord Pharma","summary":"BioXcel says new data for agitation drug Igalmi pave way for at-home use - FirstWord Pharma","headline":"BioXcel says new data for agitation drug Igalmi pave way for at-home use","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1TaTdRamNHYmtXNnJxNmZCVVViQm1WWmpwZW1aa0hlWUVRYnZlMDM4dEFBX2YxMWx6REdZS001QXZBbDFSVzFSRWppR0tMdldINUF4OUZLaXlRYm9VXzVQMHFsSWlUdw?oc=5","date":"2025-08-15","type":"pipeline","source":"timothysykes.com","summary":"Top Biotech Penny Stocks to Watch - timothysykes.com","headline":"Top Biotech Penny Stocks to Watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE5DXzNHc1g4RXhtZXVBZDd0RWhPcWVkWDcwU3JmRUlFdGlDWk1XZW5fVjdkTGd1eFQ2d25tbXAwa25oRDg5UzdWeTFTUXlYRUFIckladVctYTlZYzJWcnh4U3ZRYWtPZHp0?oc=5","date":"2025-08-07","type":"regulatory","source":"StocksToTrade","summary":"Best Biotech Stocks to Watch in August 2025: From AI Testing to FDA Fast Trackers - StocksToTrade","headline":"Best Biotech Stocks to Watch in August 2025: From AI Testing to FDA Fast Trackers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxOa0hlZXpzZjJvWDM5QlFYd3pWOG9KTDhrM01tN2pfQnJFRUZwbmRJdm1oREk4THg0ZkpQM0F6WEdKSGJ0YWNhSVowR0tMbGhRVHBneHE1aFByTG1MN3NXVDlfWEZxbHVYXzF2R2cyaUZ2cHo1UGpYUHQ4M0VvemhtamhoZHhYVWVsVEVKZlY4NmxkTFM4dE5KdDh1MHNuN2pfQmZBVVM5SVRZNHJqNkxNR2hQWmo4STNyNTdBellaY2R3aDhlUWNfczNHWDNuWXBqNUdFOFRmb0ZxQVdyZ0pEci05QWVXR29tYzlPcA?oc=5","date":"2025-05-01","type":"pipeline","source":"PR Newswire","summary":"IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight - PR Newswire","headline":"IGALMI Marks Significant Market Growth, Reaching New Heights in Treatment Accessibility | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNVk1FUWdiSDc0aTVuTzRxamg3WWRhTjRiOWc3ZTkyUmJaRlNYQl9FM3RicDZEcTlDMGdEZTlUcmtZUFFhTlhra21wLWFkemZFWXh5X0NyX3NUNXVUNDNIS2oyTXpJUEtBQnhqelNCV2VFSXdSdi1DQl9TZVhBNHFQNGlTWUhvcU1YcTdGUWQwbHpMVGVXRFBZbmI4cTMydw?oc=5","date":"2024-09-20","type":"pipeline","source":"CT Insider","summary":"New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug - CT Insider","headline":"New Haven pharma firm BioXcel cuts jobs, shifts focus to agitation drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTFBwb2tCc185VVkzT1pKMmdkZXUwQkhlTVlGX2dvWExCNW9xZldDalpMMWhsRWxmbGdzUlhva2VPRkRFY1pnN2pWdGhiQWRoZXRFY2VoYXc4WFFfTWlhYjRydGJXV1FiaWFLNTBPWkQ4N2pQYzA2?oc=5","date":"2024-06-27","type":"pipeline","source":"The Pharma Letter","summary":"BioXcel Therapeutics - The Pharma Letter","headline":"BioXcel Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxON2RBUmRIazl6cVA0SUdJWXVwdG9VR2ZiVjI3TjBGX2RMUGtUNGpsbXE4aGc1czA4ckRtQmZiNXc0MkE3MUs3T2psZHljcFdxR253eHdCY1V5Q0VreHY2Wkh5SWd2WFNVcFZ6OE9sdGNLbm9HdDlUbVc1NFpGM21qMWtfaHU4Q0JwWXM3SnhudUc1OXBpMlI3YW1QNWtQNVR1ZjQzeGxHUXhMdm9LaXJFY0xlU3VCRktWWWk0QV9RZXQwdTA1dXJhZjBuNWpvem8?oc=5","date":"2024-06-10","type":"pipeline","source":"Inside Precision Medicine","summary":"The Pharma Phoenix: BioXcel Therapeutics Uses AI to Repurpose Shelved Drugs - Inside Precision Medicine","headline":"The Pharma Phoenix: BioXcel Therapeutics Uses AI to Repurpose Shelved Drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQRU42UDZENVRzSUN3M0ZBdXVpeDYxc0pNN2JDTmQ1MU9SYjBaeDZuYXpoYnBBejdOclpsYTBXYnlIRFNhd1dNY09SWklPX283enl3T0x5V3NTTEs5RVF0TWtaVWFJc25NSmFURlhCWWo1N0kyOFItTDdNaUI3TmpLRm1RcnFkSXNVOEZNXzc3VmE5enF6N1ZrbHFpMnNsNGdDZEhhemJIRWVIUG5UQzUtQU5EcUQtNVMyNVQ4NDV3ZE5TQQ?oc=5","date":"2023-10-25","type":"regulatory","source":"Fierce Pharma","summary":"After FDA found misconduct at trial site, BioXcel touts result from 3rd-party audit and eyes filing - Fierce Pharma","headline":"After FDA found misconduct at trial site, BioXcel touts result from 3rd-party audit and eyes filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOaFl1R083ODRUc210ZjdSQ0hXb1FjSjluX0dQNVl0NkRuLW1BR2trbGpZVlZ5QUhHZGsyb2taN3psbFU1N3UxdUU5bTY5WDVGOEF5MHFzeEtfd1JxZ3prZEhJVDNNQXBMdE1laDNBMmJNbVJqVmtJclNHektEa1NHa29nLVcxdWNSWnF0dUd3Wk1laXBLLWxrXzYxcVlhN0swUGx1eldWTVp1RWc?oc=5","date":"2022-07-05","type":"pipeline","source":"citybiz","summary":"BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors - citybiz","headline":"BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":1,"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}